Cargando…
Metabolic phenotyping by treatment modality in obese women with gestational diabetes suggests diverse pathophysiology: An exploratory study
BACKGROUND AND PURPOSE: Excess insulin resistance is considered the predominant pathophysiological mechanism in obese women who develop gestational diabetes (GDM). We hypothesised that obese women requiring differing treatment modalities for GDM may have diverse underlying metabolic pathways. METHOD...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7117764/ https://www.ncbi.nlm.nih.gov/pubmed/32240196 http://dx.doi.org/10.1371/journal.pone.0230658 |
_version_ | 1783514439448788992 |
---|---|
author | White, Sara L. Begum, Shahina Vieira, Matias C. Seed, Paul Lawlor, Deborah L. Sattar, Naveed Nelson, Scott M. Welsh, Paul Pasupathy, Dharmintra Poston, Lucilla |
author_facet | White, Sara L. Begum, Shahina Vieira, Matias C. Seed, Paul Lawlor, Deborah L. Sattar, Naveed Nelson, Scott M. Welsh, Paul Pasupathy, Dharmintra Poston, Lucilla |
author_sort | White, Sara L. |
collection | PubMed |
description | BACKGROUND AND PURPOSE: Excess insulin resistance is considered the predominant pathophysiological mechanism in obese women who develop gestational diabetes (GDM). We hypothesised that obese women requiring differing treatment modalities for GDM may have diverse underlying metabolic pathways. METHODS: In this secondary analysis of the UK pregnancies Better Eating and Activity Trial (UPBEAT) we studied women from the control arm with complete biochemical data at three gestational time points; at 15–18(+6) and 27–28(+6) weeks (before treatment), and 34–36(+0) weeks (after treatment). A total of 89 analytes were measured (plasma/serum) using a targeted nuclear magnetic resonance (NMR) platform and conventional assays. We used linear regression with appropriate adjustment to model metabolite concentration, stratified by treatment group. MAIN FINDINGS: 300 women (median BMI 35kg/m(2); inter quartile range 32.8–38.2) were studied. 71 developed GDM; 28 received dietary treatment only, 20 metformin, and 23 received insulin. Prior to the initiation of treatment, multiple metabolites differed (p<0.05) between the diet and insulin-treated groups, especially very large density lipoprotein (VLDL) and high density lipoprotein (HDL) subclasses and constituents, with some differences maintained at 34–36 weeks’ gestation despite treatment. Gestational lipid profiles of the diet treatment group were indicative of a lower insulin resistance profile, when compared to both insulin-treated women and those without GDM. At 28 weeks’ the diet treatment group had lower plasma fasting glucose and insulin than women treated with insulin, yet similar to those without GDM, consistent with a glycaemic mechanism independent of insulin resistance. CONCLUSIONS/INTERPRETATION: This exploratory study suggests that GDM pathophysiological processes may differ amongst obese women who require different treatment modalities to achieve glucose control and can be revealed using metabolic profiling. |
format | Online Article Text |
id | pubmed-7117764 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-71177642020-04-09 Metabolic phenotyping by treatment modality in obese women with gestational diabetes suggests diverse pathophysiology: An exploratory study White, Sara L. Begum, Shahina Vieira, Matias C. Seed, Paul Lawlor, Deborah L. Sattar, Naveed Nelson, Scott M. Welsh, Paul Pasupathy, Dharmintra Poston, Lucilla PLoS One Research Article BACKGROUND AND PURPOSE: Excess insulin resistance is considered the predominant pathophysiological mechanism in obese women who develop gestational diabetes (GDM). We hypothesised that obese women requiring differing treatment modalities for GDM may have diverse underlying metabolic pathways. METHODS: In this secondary analysis of the UK pregnancies Better Eating and Activity Trial (UPBEAT) we studied women from the control arm with complete biochemical data at three gestational time points; at 15–18(+6) and 27–28(+6) weeks (before treatment), and 34–36(+0) weeks (after treatment). A total of 89 analytes were measured (plasma/serum) using a targeted nuclear magnetic resonance (NMR) platform and conventional assays. We used linear regression with appropriate adjustment to model metabolite concentration, stratified by treatment group. MAIN FINDINGS: 300 women (median BMI 35kg/m(2); inter quartile range 32.8–38.2) were studied. 71 developed GDM; 28 received dietary treatment only, 20 metformin, and 23 received insulin. Prior to the initiation of treatment, multiple metabolites differed (p<0.05) between the diet and insulin-treated groups, especially very large density lipoprotein (VLDL) and high density lipoprotein (HDL) subclasses and constituents, with some differences maintained at 34–36 weeks’ gestation despite treatment. Gestational lipid profiles of the diet treatment group were indicative of a lower insulin resistance profile, when compared to both insulin-treated women and those without GDM. At 28 weeks’ the diet treatment group had lower plasma fasting glucose and insulin than women treated with insulin, yet similar to those without GDM, consistent with a glycaemic mechanism independent of insulin resistance. CONCLUSIONS/INTERPRETATION: This exploratory study suggests that GDM pathophysiological processes may differ amongst obese women who require different treatment modalities to achieve glucose control and can be revealed using metabolic profiling. Public Library of Science 2020-04-02 /pmc/articles/PMC7117764/ /pubmed/32240196 http://dx.doi.org/10.1371/journal.pone.0230658 Text en © 2020 White et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article White, Sara L. Begum, Shahina Vieira, Matias C. Seed, Paul Lawlor, Deborah L. Sattar, Naveed Nelson, Scott M. Welsh, Paul Pasupathy, Dharmintra Poston, Lucilla Metabolic phenotyping by treatment modality in obese women with gestational diabetes suggests diverse pathophysiology: An exploratory study |
title | Metabolic phenotyping by treatment modality in obese women with gestational diabetes suggests diverse pathophysiology: An exploratory study |
title_full | Metabolic phenotyping by treatment modality in obese women with gestational diabetes suggests diverse pathophysiology: An exploratory study |
title_fullStr | Metabolic phenotyping by treatment modality in obese women with gestational diabetes suggests diverse pathophysiology: An exploratory study |
title_full_unstemmed | Metabolic phenotyping by treatment modality in obese women with gestational diabetes suggests diverse pathophysiology: An exploratory study |
title_short | Metabolic phenotyping by treatment modality in obese women with gestational diabetes suggests diverse pathophysiology: An exploratory study |
title_sort | metabolic phenotyping by treatment modality in obese women with gestational diabetes suggests diverse pathophysiology: an exploratory study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7117764/ https://www.ncbi.nlm.nih.gov/pubmed/32240196 http://dx.doi.org/10.1371/journal.pone.0230658 |
work_keys_str_mv | AT whitesaral metabolicphenotypingbytreatmentmodalityinobesewomenwithgestationaldiabetessuggestsdiversepathophysiologyanexploratorystudy AT begumshahina metabolicphenotypingbytreatmentmodalityinobesewomenwithgestationaldiabetessuggestsdiversepathophysiologyanexploratorystudy AT vieiramatiasc metabolicphenotypingbytreatmentmodalityinobesewomenwithgestationaldiabetessuggestsdiversepathophysiologyanexploratorystudy AT seedpaul metabolicphenotypingbytreatmentmodalityinobesewomenwithgestationaldiabetessuggestsdiversepathophysiologyanexploratorystudy AT lawlordeborahl metabolicphenotypingbytreatmentmodalityinobesewomenwithgestationaldiabetessuggestsdiversepathophysiologyanexploratorystudy AT sattarnaveed metabolicphenotypingbytreatmentmodalityinobesewomenwithgestationaldiabetessuggestsdiversepathophysiologyanexploratorystudy AT nelsonscottm metabolicphenotypingbytreatmentmodalityinobesewomenwithgestationaldiabetessuggestsdiversepathophysiologyanexploratorystudy AT welshpaul metabolicphenotypingbytreatmentmodalityinobesewomenwithgestationaldiabetessuggestsdiversepathophysiologyanexploratorystudy AT pasupathydharmintra metabolicphenotypingbytreatmentmodalityinobesewomenwithgestationaldiabetessuggestsdiversepathophysiologyanexploratorystudy AT postonlucilla metabolicphenotypingbytreatmentmodalityinobesewomenwithgestationaldiabetessuggestsdiversepathophysiologyanexploratorystudy AT metabolicphenotypingbytreatmentmodalityinobesewomenwithgestationaldiabetessuggestsdiversepathophysiologyanexploratorystudy |